Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP865625.RAckix8TIDbSIOWVsFLN7OgNCWXDC_iTH41-xxTiYfMt4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP865625.RAckix8TIDbSIOWVsFLN7OgNCWXDC_iTH41-xxTiYfMt4130_assertion type Assertion NP865625.RAckix8TIDbSIOWVsFLN7OgNCWXDC_iTH41-xxTiYfMt4130_head.
- NP865625.RAckix8TIDbSIOWVsFLN7OgNCWXDC_iTH41-xxTiYfMt4130_assertion description "[Herein, we show that in vivo administration of all-trans-retinoic acid (ATRA) or the histone deacetylase inhibitor sodium valproate (VPA) to patients affected with acute myeloid leukaemia (AML) M3 or M1 respectively, leads to the induction of transcription and expression of NKG2D-L at the surface of leukaemic cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP865625.RAckix8TIDbSIOWVsFLN7OgNCWXDC_iTH41-xxTiYfMt4130_provenance.
- NP865625.RAckix8TIDbSIOWVsFLN7OgNCWXDC_iTH41-xxTiYfMt4130_assertion evidence source_evidence_literature NP865625.RAckix8TIDbSIOWVsFLN7OgNCWXDC_iTH41-xxTiYfMt4130_provenance.
- NP865625.RAckix8TIDbSIOWVsFLN7OgNCWXDC_iTH41-xxTiYfMt4130_assertion SIO_000772 19151770 NP865625.RAckix8TIDbSIOWVsFLN7OgNCWXDC_iTH41-xxTiYfMt4130_provenance.
- NP865625.RAckix8TIDbSIOWVsFLN7OgNCWXDC_iTH41-xxTiYfMt4130_assertion wasDerivedFrom befree-20150227 NP865625.RAckix8TIDbSIOWVsFLN7OgNCWXDC_iTH41-xxTiYfMt4130_provenance.
- NP865625.RAckix8TIDbSIOWVsFLN7OgNCWXDC_iTH41-xxTiYfMt4130_assertion wasGeneratedBy ECO_0000203 NP865625.RAckix8TIDbSIOWVsFLN7OgNCWXDC_iTH41-xxTiYfMt4130_provenance.